Deals channel feed – Endpoints News

Deals channel feed

Boehringer builds out NASH pipeline with up to $870M deal with South Korea's Yuhan

6 years ago

Seducing Pfizer: How Array’s team patiently worked up the ladder to win an $11.4B bid from Albert Bourla

6 years ago

Eyeing a drug launch in early ’20, Esperion lines up a new, $200M funding deal

6 years ago

Top analyst finds a silver lining in AbbVie’s $63B Allergan buyout — but there’s a catch

6 years ago

The top 15 mega-deals in biopharma: AbbVie and Bristol-Myers acquisitions stir fresh debate over what's too big to buy

6 years ago

AbbVie's $63B buyout spotlights the return of major M&A deals — despite the backlash

6 years ago

Eyeing a $500M peak sales pot, Almirall doubles down on lebrikizumab as Dermira lines up PhIII

6 years ago

AbbVie seals $63B deal to buy a troubled Allergan — spelling out $1B in R&D cuts

6 years ago

Genfit goes to China with a deal worth up to $228M for NASH drug

6 years ago

In surprise switch, Bristol-Myers is selling off blockbuster Otezla, promising to complete Celgene acquisition — just later

6 years ago

Analyst call with Allergan execs stokes anticipation of a plan to split the company in ‘a month or two’

6 years ago

Gilead baits new alliance with $45M upfront, diving into the busy protein degradation field

6 years ago

Investor day prep at Merck includes a new strategy to pick up the pace on M&A — report

6 years ago

'It's a growth play': Catalent acquires Bristol-Myers' European launch pad, expanding global CDMO ops

6 years ago

Sanofi aligns itself with Google to streamline drug development

6 years ago

Sanofi Genzyme deserts gene therapy developer Voyager Therapeutics

6 years ago

As Bristol-Myers/Celgene tie up loose ends, BeiGene pockets $150M from PD-1 breakup

6 years ago

Gene therapy R&D deals turn red hot as Big Pharma steps up to play

6 years ago

Pfizer CEO Albert Bourla is back in the M&A game, but why is he paying $11.4B for Array?

6 years ago

Cue the M&A chatter: UniQure is scouting for a buyout deal as gene therapy field sizzles — report

6 years ago

GSK's Barron joins hands with Doudna, Weissman to deploy CRISPR tech in drug discovery

6 years ago

Merck makes a $773M bet on TGFβ, acquiring a three-year-old biotech

6 years ago

Investors fret as new regulatory probes spur fresh delays to Roche's $4.3B Spark buyout

6 years ago

R&D leader Vertex executes a $420M cash gambit to dominate gene editing field for Duchenne MD

6 years ago

First page Previous page 102 103 104105106 107 108 Next page Last page